Compare SCKT & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCKT | ONCO |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.0M |
| IPO Year | 1996 | 2021 |
| Metric | SCKT | ONCO |
|---|---|---|
| Price | $0.53 | $0.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 166.0K | ★ 388.6K |
| Earning Date | 05-05-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,078,332.00 | $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.38 | $0.09 |
| 52 Week High | $2.79 | $6.73 |
| Indicator | SCKT | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 43.93 |
| Support Level | $0.38 | $0.61 |
| Resistance Level | $0.99 | $1.02 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 26.53 | 15.75 |
Socket Mobile Inc is a producer of data capture products. The company's products are integrated into mobile applications used in mobile point of sale (mPOS), commercial services (field workers), asset tracking, manufacturing process and quality control, transportation and logistics (goods tracking and movement), event management (ticketing, entry, access control, and identification), medical and education. The company offers barcode scanning products for both one-dimensional, including imager and laser, and two-dimensional barcode scanning in standard and durable cases. The company's geographical segments are the United States, Europe, Asia and Rest of the world, of which the majority of the revenue is generated from the United States.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.